ArticleBMC genomic data2026
Exploring the functional role of palmitoylation genes in clear cell renal cell carcinoma and their impact on tumor microenvironment.
Article in BMC genomic data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe current work focused on elucidating the regulatory mechanisms of palmitoylation-related genes (PRGs) in influencing the occurrence and development of clear cell renal cell carcinoma (ccRCC), and identifying possible biomarkers and therapeutic targets.
methodsIntegrative analyses were performed using multiple databases. Two-sample Mendelian randomization (MR) was first applied for identifying PRGs causally associated with ccRCC. Findings were then validated by summary-data-based Mendelian randomization (SMR), bioinformatics analyses, and experimental verification. Functional enrichment and molecular docking were used to predict target interactions, while single-cell transcriptomic analysis was performed for assessing the relations of key PRGs with the tumor microenvironment (TME). Mediation analysis further explored upstream and downstream regulatory mechanisms.
resultsIn total, 22 PRGs associated with ccRCC were identified. Among these, ZDHHC18 emerged as a significant risk factor based on both MR and SMR results. Bioinformatics, molecular docking, and laboratory assays revealed that ZDHHC18 was upregulated and validated LYPLA2 as its downstream palmitoylation target. Pathway enrichment and single-cell analyses indicated that ZDHHC18 might shape immune heterogeneity in ccRCC by influencing multiple immune cell populations within the TME. Mediation analysis suggested that mitochondrial DNA copy number (mtDNA-cn) regulated ZDHHC18 expression, which in turn promoted ccRCC progression through four specific immune cell traits.
conclusionThis study defines an mtDNA-cn-ZDHHC18-immune cell traits axis that mechanistically links mitochondrial function, palmitoylation, and immune modulation in ccRCC. These findings expand the current understanding of palmitoylation in renal cancer biology and identify ZDHHC18 as a potential metabolic-immune regulator and therapeutic target. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.